Vtv Therapeutics Inc (VTVT)

Jun 12, 2025

vTv Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks

Jun 12, 2025

Jun 12, 2025

Transcript : VTv Therapeutics Inc.Special Call - MarketScreener

Jun 12, 2025

Jun 11, 2025

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series - GlobeNewswire

Jun 11, 2025

Jun 11, 2025

vTv Therapeutics Showcases First-in-Class Type 1 Diabetes Treatment at HC Wainwright | VTVT Stock News - Stock Titan

Jun 11, 2025

Jun 06, 2025

(VTVT) Trading Signals - news.stocktradersdaily.com

Jun 06, 2025

May 26, 2025

(VTVT) Technical Data - news.stocktradersdaily.com

May 26, 2025

May 21, 2025

vTv resumes Phase III oral T1D drug study - The Pharma Letter

May 21, 2025

May 19, 2025

vTv Therapeutics appoints new CFO amid Phase 3 trial By Investing.com - Investing.com South Africa

May 19, 2025

May 19, 2025

vTv Therapeutics Appoints New CFO Amidst Phase 3 Trial - TipRanks

May 19, 2025

May 19, 2025

vTv Therapeutics Appoints Michael Tung, M.D., MBA, As Chief Financial Officer - citybiz

May 19, 2025

May 19, 2025

VTv Therapeutics Names Michael Tung as Finance Chief - marketscreener.com

May 19, 2025

May 19, 2025

vTv Therapeutics (VTVT) Appoints New CFO | VTVT Stock News - GuruFocus

May 19, 2025

May 19, 2025

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Fina - GuruFocus

May 19, 2025

May 19, 2025

VTv Therapeutics Names Michael Tung CFO, Effective Immediately - Nasdaq

May 19, 2025

May 19, 2025

vTv Therapeutics appoints new CFO amid Phase 3 trial - Investing.com

May 19, 2025

May 19, 2025

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief - GlobeNewswire

May 19, 2025

May 19, 2025

vTv Therapeutics Advances First-in-Class Oral Type 1 Diabetes Drug as New CFO Joins - Stock Titan

May 19, 2025

May 19, 2025

Vtv Therapeutics Inc. Appoints Michael Tung as Chief Financial Officer, Effective May 19, 2025 - MarketScreener

May 19, 2025

May 17, 2025

VTv Therapeutics: Q1 Earnings Snapshot - Bluefield Daily Telegraph

May 17, 2025

May 16, 2025

How to Take Advantage of moves in (VTVT) - news.stocktradersdaily.com

May 16, 2025

May 16, 2025

vTv Therapeutics Highlights Cadisegliatin’s Potential for Diabetes - TipRanks

May 16, 2025

May 15, 2025

VTVT Advances Cadisegliatin Program with Phase 3 Study | VTVT St - GuruFocus

May 15, 2025

May 15, 2025

vTv Therapeutics advances type 1 diabetes trial By Investing.com - Investing.com South Africa

May 15, 2025

May 15, 2025

vTv Therapeutics Inc Reports Q1 2025 EPS of -$0.77, Beating Estimates; Net Loss at $5.1 Million - GuruFocus

May 15, 2025

May 15, 2025

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update - The Manila Times

May 15, 2025

May 15, 2025

vTv Therapeutics Accelerates Timeline for First-Ever Oral Type 1 Diabetes Drug as Phase 3 Trial Advances - Stock Titan

May 15, 2025

May 15, 2025

VTV Therapeutics Announces Reinitiation Of Screening In CATT1 Phase 3 Trial - marketscreener.com

May 15, 2025

May 15, 2025

vTv Therapeutics advances type 1 diabetes trial - Investing.com Australia

May 15, 2025

May 15, 2025

VTv Therapeutics Resumes Cadisegliatin Testing in Type 1 Diabetes - marketscreener.com

May 15, 2025

May 15, 2025

vTv Therapeutics (VTVT) Resumes Phase 3 Trial for Diabetes Treat - GuruFocus

May 15, 2025

May 15, 2025

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes | VTVT Stock New - GuruFocus

May 15, 2025

May 15, 2025

vTv Therapeutics (VTVT) Resumes Phase 3 Trial for Diabetes Treatment | VTVT Stock News - GuruFocus

May 15, 2025

May 15, 2025

vTv Therapeutics Announces Reinitiation of CATT1 Phase 3 Trial for Cadisegliatin, Shortens Duration to Expedite Topline Data Expected in 2026 - Nasdaq

May 15, 2025

May 15, 2025

vTv Therapeutics Announces Reinitiation of Screening in - GlobeNewswire

May 15, 2025

May 15, 2025

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes - Stock Titan

May 15, 2025

May 06, 2025

How the (VTVT) price action is used to our Advantage - news.stocktradersdaily.com

May 06, 2025

May 05, 2025

vTv Therapeutics Inc expected to post a loss of 81 cents a shareEarnings Preview - TradingView

May 05, 2025

May 05, 2025

Geode Capital Management LLC Has $158,000 Holdings in vTv Therapeutics Inc. (NASDAQ:VTVT) - Defense World

May 05, 2025

May 01, 2025

vTv Therapeutics (VTVT) to Release Quarterly Earnings on Thursday - Defense World

May 01, 2025

Apr 22, 2025

vTv Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:VTVT - Benzinga

Apr 22, 2025

Apr 16, 2025

vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at StockNews.com - Defense World

Apr 16, 2025

Apr 12, 2025

vTv Therapeutics Appoints Barry Brown as Interim CFO - MSN

Apr 12, 2025

Apr 11, 2025

vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at HC Wainwright - Defense World

Apr 11, 2025

Apr 11, 2025

Q1 Earnings Forecast for VTVT Issued By HC Wainwright - Defense World

Apr 11, 2025

Apr 09, 2025

HC Wainwright Initiates vTv Therapeutics With Buy Rating, $36 Price Target - MarketScreener

Apr 09, 2025

Apr 09, 2025

This Couchbase Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Apr 09, 2025

Apr 09, 2025

HC Wainwright & Co. Initiates Coverage of vTv Therapeutics (VTVT) with Buy Recommendation - Nasdaq

Apr 09, 2025

Apr 09, 2025

H.C. Wainwright sets $36 target for vTv Therapeutics stock By Investing.com - Investing.com Canada

Apr 09, 2025